Gonadorelin Acetate

2mg Vial

2 September 2026Updated 2 September 2026

Gonadorelin Acetate

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Gonadorelin Acetate.

Create free account Member login

Full range of benefits for Gonadorelin Acetate

Stimulates endogenous LH and FSH release via GnRH receptor activation

Useful diagnostically to assess pituitary gonadotroph function

Helps induce ovulation when administered in pulsatile regimens

Can restore spermatogenesis in some cases of hypogonadotropic hypogonadism

Can initiate pubertal development in GnRH-deficient delayed puberty

Can be used as an ovulation trigger in assisted reproduction protocols

Short plasma half-life allows fine titration of gonadotropin response

May reduce need for exogenous gonadotropins in selected patients

Valuable research tool for studying hypothalamic–pituitary–gonadal axis dynamics

Helps assess pituitary responsiveness to guide individualized treatment planning

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Works exceptionally well with this peptide

Human chorionic gonadotropin (hCG)

hCG provides LH-like activity that supports ovulation and luteal function and is commonly used with gonadorelin-initiated follicular stimulation to enhance ovulatory response and luteal support.

Recombinant FSH (follitropin) / Human menopausal gonadotropin (hMG)

Exogenous FSH-containing preparations augment follicular development driven by endogenous LH/FSH release from pulsatile gonadorelin, improving ovarian response in assisted reproduction.

Pulsatile gonadorelin combined with gonadotropin therapy

When used together in hypogonadotropic hypogonadism, pulsatile gonadorelin restores physiological gonadotropin secretion while adjunct gonadotropins accelerate gonadal maturation and fertility outcomes.

All interaction categories

Synergistic (3)

Human chorionic gonadotropin (hCG): hCG provides LH-like activity that supports ovulation and luteal function and is commonly used with gonadorelin-initiated follicular stimulation to enhance ovulatory response and luteal support.
Recombinant FSH (follitropin) / Human menopausal gonadotropin (hMG): Exogenous FSH-containing preparations augment follicular development driven by endogenous LH/FSH release from pulsatile gonadorelin, improving ovarian response in assisted reproduction.
Pulsatile gonadorelin combined with gonadotropin therapy: When used together in hypogonadotropic hypogonadism, pulsatile gonadorelin restores physiological gonadotropin secretion while adjunct gonadotropins accelerate gonadal maturation and fertility outcomes.

Compatible (3)

Folic acid (folate) supplementation: Folate supplementation is a neutral, supportive therapy during fertility treatment with no direct pharmacodynamic interaction with gonadorelin.
Micronized progesterone (luteal support): Progesterone given for luteal phase support is generally compatible with gonadorelin protocols and does not directly antagonize pulsatile GnRH-mediated gonadotropin release.
Paracetamol (acetaminophen): Non-opioid analgesics such as paracetamol have no clinically relevant interaction with gonadorelin and are safe for symptomatic use during treatment.

Monitor (4)

Exogenous estrogens / combined oral contraceptives: Estrogen therapy or combined oral contraceptives suppress pituitary responsiveness and can reduce the efficacy of gonadorelin, so gonadotropin levels and clinical response should be monitored and timing of therapy adjusted.
Androgen therapy (testosterone preparations): Exogenous androgens can suppress the hypothalamic–pituitary–gonadal axis and blunt gonadorelin-induced gonadotropin responses, requiring monitoring of LH/FSH and sex steroid levels and potential dose modification.
Opioid analgesics: Chronic or high-dose opioid use can suppress GnRH secretion and reduce therapeutic response to gonadorelin, warranting monitoring of clinical efficacy and sex hormone concentrations.
Long‑acting GnRH agonists / GnRH antagonists (e.g., leuprolide, cetrorelix): Concurrent or recent use of long‑acting GnRH agonists or antagonists profoundly alters pituitary responsiveness, so scheduling and endocrine markers must be closely monitored to avoid treatment failure or conflicting effects.

Avoid (4)

Dopamine antagonists (antipsychotics, metoclopramide): Medications that raise prolactin can suppress GnRH-driven gonadotropin secretion and should be evaluated for prolactin levels and alternative therapies before combining with gonadorelin.
Clomiphene citrate (selective estrogen receptor modulator): Clomiphene and gonadorelin both modulate gonadotropin secretion and their combined effects can be unpredictable and increase the risk of ovarian hyperstimulation, requiring specialist supervision.
Systemic corticosteroids (e.g., prednisone at immunosuppressive doses): High‑dose or prolonged systemic glucocorticoids can suppress the HPG axis and alter response to gonadorelin, so clinical endocrine status should be reviewed prior to coadministration.
Selective serotonin reuptake inhibitors (SSRIs): Some SSRIs may affect prolactin or sexual function and can indirectly influence clinical response to fertility treatments, so risks and benefits should be assessed before concurrent use.